A group of researchers at Nottingham University in the U.K. are planning to launch a human trial of a new vaccine for metastatic melanoma. Lead researcher Professor Lindy Durrant says that the vaccine contains DNA and tumor fragments so that it will activate only specific immune cells rather than the entire immune system. Report